Latest Sydney News

Page 2 of 91
Noumi shareholders and optionholders have backed Arrovest’s proposed schemes, clearing the main voting hurdle in the takeover. The transaction still requires Supreme Court of New South Wales approval and satisfaction or waiver of other conditions.
Victor Sage
Victor Sage
5 Nov 2026
News Corp opened fiscal 2027 with revenue up 6% and net income up 43%, led by Dow Jones, digital real estate and book publishing. The quarter also exposed a sharper split in the portfolio: News Media weakened and free cash flow turned negative.
Victor Sage
Victor Sage
5 Nov 2026
Goodman Group is targeting 9% growth in FY27 operating EPS as its global development pipeline expands amid tight power, land and planning constraints. The group’s work in progress reached $19.7 billion, with data centres accounting for 79% of the total.
Eva Park
Eva Park
4 Nov 2026
Global Masters Fund will pay its first-ever dividend, a 15.0 cent per share special distribution that is fully franked and sourced from taxable capital gains. The payment marks a deliberate transition for the listed investment company, not the start of a regular dividend stream.
Claire Turing
Claire Turing
2 Nov 2026
FortifAI has launched the production-ready version of its NOL8 AI Data Plane ahead of schedule, opening the door to paid enterprise proof-of-value engagements. The ASX-listed technology company ended September with A$17.3 million in cash and no debt, but still needs to convert technical validation into contracts and revenue.
Sophie Babbage
Sophie Babbage
30 Oct 2026
ClearVue Technologies has converted its Canva project into a binding subcontract and secured certifications that broaden the market for its solar glass. But the ASX-listed company ended Q1 FY27 with A$2.281 million in cash, A$2.666 million of quarterly operating outflows and estimated funding for just 1.3 quarters.
Victor Sage
Victor Sage
30 Oct 2026
Vertex Minerals has secured approval for round-the-clock underground operations at its Reward Gold Mine, removing the company’s stated biggest production constraint. The operational opening arrives alongside modest quarterly output, a sharply revised resource and reported cash coverage of less than half a quarter.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Micro-X has reported a sharp improvement in Rover order activity and more than $3 million in annualised cost savings, while redirecting its strategy towards medical CT. The September quarter still consumed $4.4 million in operating cash, leaving funding dependent on further note proceeds, an expected tax refund and milestone receipts.
Victor Sage
Victor Sage
30 Oct 2026
BCAL Diagnostics has completed clinical validation for BREASTESTplus 2 across all breast densities and is targeting a November launch, while expanding Avantect Multicancer access. The commercial push comes alongside $1.895 million in quarterly operating cash outflows, only $580,000 in cash at quarter end and a growing strategic stake in Genetic Signatures.
Ada Torres
Ada Torres
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM Alzheimer’s trial after completing its first quarter as an ASX-listed company. The medical technology group ended September with $7.1 million in cash, while a device milestone unlocked a further $692,578 in non-dilutive funding.
Victor Sage
Victor Sage
30 Oct 2026
OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive